Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
CRI Worldwide, LLC
mi
from
Willingboro, NJ
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Erie County Medical Center, Corp
mi
from
Buffalo, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Erie County Medical Center, Corp
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Comprehensive Clinical Development, Inc
mi
from
Fresh Meadows, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Comprehensive Clinical Development, Inc
mi
from
Fresh Meadows, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Finger Lakes Clinical Research
mi
from
Rochester, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Finger Lakes Clinical Research
mi
from
Rochester, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Behavioral Medical Research of Staten Island
mi
from
Staten Island, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Behavioral Medical Research of Staten Island
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Oklahoma Clinical Research
mi
from
Oklahoma City, OK
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Oklahoma Clinical Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Cutting Edge Research Group
mi
from
Oklahoma City, OK
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Cutting Edge Research Group
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
CRI Worldwide - Kirkbride
mi
from
Philadelphia, PA
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
CRI Worldwide - Kirkbride
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Lincoln Research
mi
from
Lincoln, RI
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Lincoln Research
mi
from
Lincoln, RI
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
FutureSearch Clinical Trials LP
mi
from
Austin, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Community Clinical Research
mi
from
Austin, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Pillar Clinical Research, LLC
mi
from
Dallas, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Family Psychiatry of the Woodlands
mi
from
The Woodlands, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Family Psychiatry of the Woodlands
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Department of Psychiatry, University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Department of Psychiatry, University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Frontier Institute
mi
from
Spokane, WA
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Frontier Institute
mi
from
Spokane, WA
Click here to add this to my saved trials
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
Status: Enrolling
Updated:  7/8/2013
Columbia University & New York State Psyciatric Institute
mi
from
New York, NY
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
Status: Enrolling
Updated: 7/8/2013
Columbia University & New York State Psyciatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Garden Grove, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Glendale, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
National City, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
National City, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Oakland, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Pico Rivera, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
San Diego, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Miramar, FL
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Miramar, FL
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Atlanta, GA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Marlton, NJ
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Staten Island, NY
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Staten Island, NY
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Philadelphia, PA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
mi
from
Irving, TX
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
mi
from
Irving, TX
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Chino, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Chino, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Garden Grove, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
National City, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Oceanside, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Santa Ana, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
San Diego, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Torrance, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Bradenton, FL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Maitland, FL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Chicago, IL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Hoffman Estates, IL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Lake Charles, LA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
St. Louis, MO
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Marlton, NJ
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Cedarhurst, NY
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
New York, NY
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
DeSoto, TX
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
DeSoto, TX
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from
Houston, TX
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia
Status: Enrolling
Updated:  7/22/2013
Clinical Research Facility
mi
from
San Diego, CA
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia
Status: Enrolling
Updated: 7/22/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials